Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 140 of the 142 references it cites were found in a registry or an index; 42 of the 101 sources its claims cite were checked for support.

The HPA Axis as Target for Depression

Open access
Menke, Andreas · 2024 · Current Neuropharmacology

Abstract

Major depressive disorder (MDD) is a stress-related mental disorder with a lifetime prevalence of 20% and, thus, is one of the most prevalent mental health disorders worldwide. Many studies with a large number of patients support the notion that abnormalities of the hypothalamus-pituitaryadrenal (HPA) axis are crucial for the development of MDD. Therefore, a number of strategies and drugs have been investigated to target different components of the HPA axis: 1) corticotrophinreleasing hormone (CRH) 1 receptor antagonists; 2) vasopressin V1B receptor antagonists, 3) glucocorticoid receptor antagonists, and 4) FKBP5 antagonists. Until now, V1B receptor antagonists and GR antagonists have provided the most promising results. Preclinical data also support antagonists of FKBP5, which seem to be partly responsible for the effects exerted by ketamine. However, as HPA axis alterations occur only in a subset of patients, specific treatment approaches that target only single components of the HPA axis will be effective only in this subset of patients. Companion tests that measure the function of the HPA axis and identify patients with an impaired HPA axis, such as the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the molecular dexamethasonesuppression (mDST) test, may match the patient with an effective treatment to enable patient-tailored treatments in terms of a precision medicine approach.

Overview

CoChat Summary

TL;DR

This narrative review argues that HPA axis abnormalities are robustly documented in MDD but occur only in a subset of patients, so treatments targeting single HPA axis components will likely require companion tests for patient selection. It summarizes clinical and preclinical evidence for CRH1, V1B, GR, and FKBP5 antagonists, with V1B antagonists and mifepristone showing the most promising results to date.

Key findings

  • MDD has a lifetime prevalence of around 20% and heritability of around 40%; more than 50% of patients fail the first antidepressant prescribed, and about 30% do not respond after several treatment attempts. HPA axis hyperactivity with impaired negative feedback is robustly found in MDD, but not all patients with MDD display HPA axis dysfunction.
  • A meta-analysis of over 16 randomized controlled trials and 7 open-label trials with 2972 subjects found a significant difference in efficacy across HPA-axis-targeting medications versus controls; subgroup analyses showed significant differences favoring the GR antagonist mifepristone and V1B receptor antagonists.
  • V1B antagonist trials were mixed: SSR149415 at 250 mg, but not 100 mg, led to greater HDRS reduction after 8 weeks, though the trial failed because the escitalopram comparator did not achieve significant HDRS reduction; another trial with 100 mg and 250 mg showed no significant improvement versus placebo; doses above 250 mg significantly reduced cortisol response. ABT-436 showed favorable effects on 2 of 5 MASQ subscales but no significant HDRS effect; TS-121 produced a larger MADRS reduction than placebo after 6 weeks, but the effect was not statistically significant.
  • Mifepristone trials (4 double-blind, 2 open-label) suggested significant reduction in psychotic symptoms, the primary outcome, but depressive symptoms were secondary and often not significantly improved versus placebo; a combined analysis of five placebo-controlled trials (cases n = 833, placebo n = 627) found significant psychotic symptom reduction when plasma concentrations were within the therapeutic range (about 1600 ng/ml, equating to around 1200 mg/day). CRH1 antagonist R121919 reduced HDRS but was withdrawn for liver enzyme elevations; CP-316,311 failed to improve depressive symptoms; FKBP5 antagonists SAFit1 and SAFit2 improved stress-coping and neuroendocrine feedback in preclinical models but have not yet been tested in clinical samples.

Methods

  • Narrative review; no primary data, systematic search strategy, or meta-analysis conducted by the author is described.
  • Synthesizes preclinical and clinical literature on the HPA axis in MDD, including trials of CRH1 receptor antagonists, V1B receptor antagonists, GR antagonists, and FKBP5 antagonists, as well as HPA axis tests such as the DST, dex-CRH test, and molecular DST (mDST).
  • Main analysis is a qualitative synthesis of cited studies, reporting selected trial outcomes and meta-analytic findings from prior work.

Limitations

  • Stated: HPA axis alterations occur only in a subset of MDD patients; specific HPA-axis-targeting compounds improve depressive symptoms only in a certain proportion of patients; dex-CRH findings are heterogeneous with modest effect sizes; DST sensitivity is only 20–50%; mifepristone trials were often shorter than usual trials and depressive symptoms were secondary outcomes; FKBP5 antagonists have not yet been tested in clinical samples.
  • Evident: as a narrative review, it does not describe a systematic search strategy, risk-of-bias assessment, or quantitative synthesis, so conclusions rely on selected cited studies.
  • Evident: no primary data or new experimental results are presented.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2174/1570159x21666230811141557

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. (1) The hypothalamus-pituitary-adrenal (HPA) axis: The corticotrophin-releasing hormone (CRH) is released by the paraventricular nucleus (PVN) of the hypothalamus and then binds to the corticotrophin-releasing hormone 1 CRH1 receptors in the anterior pituitary (target 1). The secretion of adrenocorticotropic hormone (ACTH) into the peripheral circulation is activated. In addition, arginine-vasopressin (AVP) is also produced in the PVN and released into the pituitary circulation, where it potentiates the effects of CRH on ACTH release via activation of V1B receptors (target 2). ACTH induces the release of cortisol in the adrenal cortex, which exerts its effects on peripheral cells. Cortisol also activates the negative feedback loops by stimulating the glucocorticoid receptors (GR) in the pituitary and the hypothalamus to reinstate homeostasis (target 3). The GR complex consists of the co-chaperones FKBP51 and FKBP52 of the heat-shock protein hsp90 dimer and the co-chaperone molecule p23. When FKBP51 is bound to the receptor complex, cortisol binds with lower affinity (target 4). After cortisol binding, FKBP51 is exchanged against FKBP52, and nuclear translocation and transcriptional activity are enabled. In terms of an ultrashort negative feedback loop, GR activation leads to transcription and translation of FKBP51, which reduces GR sensitivity. Reprinted from Psychoneuroendocrinology, Volume 91, Carolin Leistner, Andreas Menke, How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders, 235-260, Copyright (2018), with permission from Elsevier.
Fig. (1) The hypothalamus-pituitary-adrenal (HPA) axis: The corticotrophin-releasing hormone (CRH) is released by the paraventricular nucleus (PVN) of the hypothalamus and then binds to the corticotrophin-releasing hormone 1 CRH1 receptors in the anterior pituitary (target 1). The secretion of adrenocorticotropic hormone (ACTH) into the peripheral circulation is activated. In addition, arginine-vasopressin (AVP) is also produced in the PVN and released into the pituitary circulation, where it potentiates the effects of CRH on ACTH release via activation of V1B receptors (target 2). ACTH induces the release of cortisol in the adrenal cortex, which exerts its effects on peripheral cells. Cortisol also activates the negative feedback loops by stimulating the glucocorticoid receptors (GR) in the pituitary and the hypothalamus to reinstate homeostasis (target 3). The GR complex consists of the co-chaperones FKBP51 and FKBP52 of the heat-shock protein hsp90 dimer and the co-chaperone molecule p23. When FKBP51 is bound to the receptor complex, cortisol binds with lower affinity (target 4). After cortisol binding, FKBP51 is exchanged against FKBP52, and nuclear translocation and transcriptional activity are enabled. In terms of an ultrashort negative feedback loop, GR activation leads to transcription and translation of FKBP51, which reduces GR sensitivity. Reprinted from Psychoneuroendocrinology, Volume 91, Carolin Leistner, Andreas Menke, How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders, 235-260, Copyright (2018), with permission from Elsevier.CC BY · PubMed Central

Verification

Claims the paper makes

34 Valid · 1 Not valid · 29 Not checked · 8 Own results and interpretations

41 more claims · 16 with their cited sources checked

Create a free account to see all 72 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 142 references

Cited by

See all 131

Metadata

Authors
Menke, A.
Affiliations
Ludwig-Maximilians-Universität München (DE)
Corresponding author
Menke, Andreas
Venue
Current Neuropharmacology
Published
2024-05
Volume
22
Issue
5
Pages
904-915
ISSN
1570-159X (ISSN-L)
OpenAlex
W4385827296
Cited by
131
References
142
Citations by year
2026: 63 · 2025: 50 · 2024: 18
FWCI
24.35
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
major depressive disorder, hypothalamic-pituitary-adrenal axis, HPA axis dysregulation, glucocorticoid receptor antagonist, ketamine, precision medicine, stress-related disorders
MeSH terms
Corticotropin-Releasing Hormone, Depression, Major Depressive Disorder, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The HPA Axis as Target for Depression. https://app.cochat.ai/papers/10.2174/1570159x21666230811141557
The paper
Menke, A. (2024). The HPA Axis as Target for Depression. Current Neuropharmacology. https://doi.org/10.2174/1570159x21666230811141557

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.